

# Prevalence of multiple myeloma

**First published:** 21/06/2023

**Last updated:** 23/04/2024

Study

Finalised

## Administrative details

### PURI

<https://redirect.ema.europa.eu/resource/104329>

---

### EU PAS number

EUPAS104328

---

### Study ID

104329

---

### DARWIN EU® study

No

---

### Study countries

- France
  - Germany
  - United Kingdom
-

## Study description

A descriptive study to determine the complete prevalence of Multiple Myeloma in electronic health records of three European countries

---

## Study status

Finalised

## Research institutions and networks

### Institutions

#### European Medicines Agency (EMA)

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

## Contact details

### Study institution contact

Luis Pinheiro

Study contact

[luis.pinheiro@ema.europa.eu](mailto:luis.pinheiro@ema.europa.eu)

### Primary lead investigator

Luis Pinheiro

Primary lead investigator

## Study timelines

### **Date when funding contract was signed**

Planned: 03/02/2022

Actual: 03/02/2022

---

### **Study start date**

Planned: 03/02/2022

Actual: 03/02/2022

---

### **Date of final study report**

Planned: 15/03/2022

Actual: 13/05/2022

## Sources of funding

- EMA

## Study protocol

[Data analysis plan - Multiple Myeloma - 20220224 - v1\\_For Publication\\_CLEAN.pdf\(141.82 KB\)](#)

## Regulatory

### **Was the study required by a regulatory body?**

Yes

---

### **Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

**Study topic:**

Disease /health condition

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Disease epidemiology

**Data collection methods:**

Secondary use of data

---

**Main study objective:**

to determine the complete prevalence of Multiple Myeloma in electronic health records of three European countries (France, Germany, United Kingdom).

## Study Design

**Non-interventional study design**

Other

---

**Non-interventional study design, other**

Descriptive study

## Study drug and medical condition

**Medical condition to be studied**

Plasma cell myeloma

## Population studied

## **Short description of the study population**

The study included patients with at least one encounter (consultation, prescription) to determine the prevalence of multiple myeloma, between 2015 and 2020, identified from the IMRD databases.

---

### **Age groups**

Children (2 to < 12 years)

Adolescents (12 to < 18 years)

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

---

### **Special population of interest**

Other

---

### **Special population of interest, other**

Multiple Myeloma patients

---

### **Estimated number of subjects**

10000

## **Study design details**

### **Data analysis plan**

Prevalence was determined using the any-time method. The denominator was calculated as the count of patients of all ages who are eligible, i.e. had at least one observation (consultation or prescription), during the period of interest. The numerator was computed as the count of patients that had at least one code for

Multiple Myeloma, per a list of pre-selected codes, during the period starting from the start of data collection for the patient to the end of the period of interest (i.e. complete prevalence). Results were not stratified by age or gender.

## Documents

### Study results

[Multiple Myeloma Prevalence Report - 20220513 - To be published\\_CLEAN.pdf](#)

(361.29 KB)

---

## Data management

### Data sources

#### Data source(s)

IQVIA Disease Analyzer Germany

Disease Analyzer - OMOP

---

#### Data sources (types)

[Drug dispensing/prescription data](#)

[Electronic healthcare records \(EHR\)](#)

### Use of a Common Data Model (CDM)

#### CDM mapping

No

### Data quality specifications

**Check conformance**

Unknown

---

**Check completeness**

Unknown

---

**Check stability**

Unknown

---

**Check logical consistency**

Unknown

## Data characterisation

**Data characterisation conducted**

No